Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
5 min read
Regulating tumor immune suppression, the therapeutic effect of the new generation CSF-1R inhibitors is encouraging
18 September 2023
CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade.
Drug Insights
4 min read
Exploring Dihydroergotamine Mesylate's Revolutionary R&D Successes
18 September 2023
This article summarized the latest R&D progress of Dihydroergotamine Mesylate, the Mechanism of Action for Dihydroergotamine Mesylate, and the drug target R&D trends for Dihydroergotamine Mesylate.
Latest Hotspot
3 min read
CheckMate-227 Trial Phase 3 confirms prolonged survival with Opdivo and Yervoy in Metastatic Non-Small Cell Lung Cancer
18 September 2023
Phase 3 CheckMate-227 Trial's findings confirm enduring, extended survival with Opdivo combined with Yervoy with Metastatic Non-Small Cell Lung Cancer.
Drug Insights
4 min read
Decoding Diacerein: A Comprehensive Study of its R&D Trends
18 September 2023
This article summarized the latest R&D progress of Diacerein, the Mechanism of Action for Diacerein, and the drug target R&D trends for Diacerein.
Advanced Tech.
7 min read
Important anti-cancer drug for tackling tumors: saRNA drug
18 September 2023
Due to the small molecular weight and gene specificity of saRNA, it can be used to enhance the expression of specific proteins (products of tumor suppressor gene or haploinsufficient genes).
Drug Insights
4 min read
Deep Scientific Insights on Dabigatran Etexilate Mesylate's R&D Progress
18 September 2023
This article summarized the latest R&D progress of Dabigatran Etexilate Mesylate, the Mechanism of Action for Dabigatran Etexilate Mesylate, and the drug target R&D trends for Dabigatran Etexilate Mesylate.
Latest Hotspot
3 min read
Blue Earth Therapeutics reports encouraging findings from preclinical assessment of 225Ac-rhPSMA-10.1 of Prostate Cancer
18 September 2023
Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.
Drug Insights
4 min read
An In-depth Analysis of Betahistine Hydrochloride's R&D Progress
18 September 2023
This article summarized the latest R&D progress of Betahistine Hydrochloride, the Mechanism of Action for Betahistine Hydrochloride, and the drug target R&D trends for Betahistine Hydrochloride.
Valuable Targets
5 min read
Migraine Treatment Medication——CGRP antagonists
18 September 2023
CGRP, or calcitonin gene-related peptide, is a neuropeptide that plays a crucial role in the human body.
Drug Insights
4 min read
Artemether: Detailed Review of its Transformative R&D Success
18 September 2023
This article summarized the latest R&D progress of Artemether, the Mechanism of Action for Artemether, and the drug target R&D trends for Artemether.
Latest Hotspot
4 min read
Phase 2 Results shows the potential of Vergent Biosciences' Cancer-Specific Fluorescent Imaging Compound to Improve Success of Lung Cancer Surgeries
18 September 2023
Results from the Phase 2 clinical trial examining VGT-309 indicate that the trial drug could enhance surgeons' capacity to locate hard-to-spot and previously missed tumors in real-time, thereby potentially benefitting patient outcomes.
Drug Insights
4 min read
A Comprehensive Review of Zonisamide's R&D Innovations and Drug Target Mechanism
18 September 2023
This article summarized the latest R&D progress of Zonisamide, the Mechanism of Action for Zonisamide, and the drug target R&D trends for Zonisamide.